Devita, Hellman, and Rosenberg's Cancer

LWBK1006-26 LWW-Govindan-Review December 12, 2011 19:29

374 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

Answer 26.22. The answer is B.

Sunitinib is an oral small molecule, multitargeted receptor tyrosine kinase

inhibitor that is an active agent in the treatment of alveolar soft part

sarcoma. Imatinib, dasatinib, and nilotinib are tyrosine kinase inhibitors

that have activity against GIST. Sunitinib also is used to treat GIST.

Answer 26.23. The answer is B.

Extremity soft tissue sarcomas have the best prognosis, followed by vis-

ceral and retroperitoneal. Head and neck soft tissue sarcomas carry the

worst prognosis.